BioVectra and Keryx Biopharmaceuticals Enter Agreement for Ferric Citrate Production Expansion
BioVectra Inc., an innovative global contract development and manufacturing organization (CDMO), today announced a long-term supply agreement with Keryx Biopharmaceuticals, Inc., to manufacture Ferric Citrate, the active pharmaceutical ingredient (API) in Auryxia® tablets, a medicine approved for the treatment of two common complications of chronic kidney disease.
BioVectra Inc. brings over 45 years of contract development and manufacturing experience to the partnership, including working with Keryx to manufacture Ferric Citrate API since 2003. BioVectra will prepare for the anticipated growth in the long-term Ferric Citrate API supply needs by expanding production capacity at their headquarters facility in Charlottetown, PEI, Canada.
“This partnership is a pivotal step in our journey as BioVectra. It is a shining example of the innovation, talent and determination we have cultivated in the Atlantic Canada region. We take great pride in serving the needs of global partners and the patients they are treating,” said BioVectra President, Oliver Technow. “We are very pleased to bring an agreement of this magnitude, creating highly skilled jobs, to Charlottetown, PEI. It is another terrific accomplishment for bioscience in Atlantic Canada.”
“With the recent U.S. FDA approval of Auryxia for a second indication, it is critical that we have sufficient manufacturing capacity to support anticipated future prescription demand,” said Melissa Bradford-Klug, Chief Business Officer of Keryx Biopharmaceuticals. “BioVectra has been manufacturing the active pharmaceutical ingredient in Auryxia since 2003 and we believe they will be a great partner as we continue to expand the supply chain for Auryxia.”
“This partnership illustrates what BioVectra does best. Since Keryx first approached us for clinical supply nearly 15 years ago, we have collaborated on Auryxia’s clinical phases, registration, and commercial launch to a point where we are expanding capacity to meet increased market demand,” said Vice President of Business Development, Heather Delage. “We look forward to continuing to be an important part of Keryx’s long-term strategic supply chain.”
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team consists of approximately 200 committed people working with passion to advance the care of people with this complex disease. This dedication has resulted in two FDA-approved indications for Keryx’s first medicine, Auryxia® (ferric citrate) tablets. For more information about Keryx, please visit www.keryx.com.
About BioVectra
BioVectra is a CDMO that serves pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable service partner with a strong regulatory history, BioVectra has over 45 years of experience specializing in:
- GMP Microbial Fermentation & Purification
- Complex Chemistry
- Process & Analytical Development
For more information about BioVectra, please visit www.biovectra.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171214005332/en/
Contact information
BioVectra Inc.
Jordan MacGregor
Marketing and Communications
Manager
jmacgregor@biovectra.com
902-566-9116
ext. 6376
www.biovectra.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Hackett Group ® and Celonis Partner to Accelerate ROI With Unmatched AI + Process Intelligence Solutions6.8.2025 00:18:00 EEST | Press release
The Hackett Group, Inc. (NASDAQ: HCKT), a leading generative artificial intelligence (Gen AI) consultancy and executive advisory firm, today announced a collaboration with Celonis, a global leader in process mining, to deliver intelligent enterprise automation that drives measurable business results at unprecedented speed. Using Celonis process intelligence and The Hackett Group’s AI XPLR™ and ZBrain™ platforms – that leverage The Hackett Group’s globally recognized enterprise benchmarking and business transformation IP – companies can compare their performance against Digital World Class® performance standards. This will allow clients to quickly identify the greatest ROI opportunities and harness unmatched process intelligence and agentic workflow solutions to achieve their value realization objectives. The partnership delivers: Clarity on the right tech investments: Combining The Hackett Group’s industry benchmarks with Celonis process intelligence and its own benchmarks on leading m
IFF Reports Second Quarter 2025 Results5.8.2025 23:26:00 EEST | Press release
IFF (NYSE: IFF) reported financial results for the second quarter ended June 30, 2025. Management Commentary “IFF’s second-quarter results reflect the progress we are making to strengthen our business and advance our strategic agenda,” said Erik Fyrwald, CEO of IFF. “Our teams delivered top-line growth and improved profitability, driven by disciplined execution and a strong focus on productivity. We also made strides in reshaping our portfolio by closing the divestitures of Pharma Solutions and Nitrocellulose, and successfully completing our debt tender offering - reducing leverage to 2.5x, ahead of our target and reinforcing our financial position.” “Additionally, we announced the expected divestiture of our soy crush, concentrates, and lecithin business - furthering the evolution of our Food Ingredients portfolio toward more value-added offerings. This move aligns with our margin enhancement strategy and supports our continued evaluation of strategic alternatives for this business.”
Cooler Master’s MasterHUB Wins Red Dot Award for Design Excellence5.8.2025 22:36:00 EEST | Press release
Cooler Master, a global leader in innovative thermal solutions and PC hardware, today announced that MasterHUB has won the Red Dot Award in the 2025 Brands & Communication Design category. The Red Dot is an internationally recognized symbol of outstanding design quality, awarded by a jury of global design experts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250805404259/en/ Cooler Master's Award-Winning MasterHUB Stream Deck. This recognition highlights Cooler Master’s FreeForm 2.0 design philosophy, which empowers users to build personalized, modular systems that evolve with their needs. MasterHUB embodies this approach by offering a flexible foundation for streamers, editors, and creatives to shape their own workflows. “MasterHUB was designed to grow with you,” said Matteo Stracciari, General Manager at Cooler Master. “Whether you're mixing audio, editing video, or live streaming, the modular system adapts to your tools
Yamaha Motor: Consolidated Business Results Summary - First Half of Fiscal Year Ending December 31, 2025 -5.8.2025 20:00:00 EEST | Press release
Yamaha Motor Co., Ltd. (Tokyo: 7272) announces its consolidated business results for the first half of fiscal 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250805154633/en/ Yamaha Motor Co., Ltd. Revenues for the period were 1,277.8 billion yen (a decrease of 70.6 billion yen or 5.2% compared with the same period of the previous fiscal year), operating income was 84.1 billion yen (a decrease of 70.0 billion yen or 45.4%), and net income attributable to owners of parent was 53.1 billion (a decrease of 59.8 billion yen or 52.9%). For the first half-year consolidated accounting period, the U.S. dollar traded at 148 yen (an increase of 4 yen from the same period of the previous fiscal year) and the euro at 162 yen (an increase of 3 yen). Declining unit sales in motorcycles, personal watercraft, and golf cars led to lower revenues. For operating income, the decrease in unit sales and higher R&D expenses in the core motorcy
Textron Aviation Announces Additional Garmin Avionics Upgrade Option for Cessna Citation CJ15.8.2025 19:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced customers can now upgrade their Cessna Citation CJ1 with the all-Garmin retrofit solution following Federal Aviation Administration (FAA) supplemental type certification (STC). Customers can have the upgrade installed at any of the company’s global service network locations to add significant technological advances and new capabilities to their aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250805392790/en/ Textron Aviation announced customers can now upgrade their Cessna Citation CJ1 with the all-Garmin retrofit solution following Federal Aviation Administration (FAA) supplemental type certification (STC). The Garmin avionics upgrade — including the new, larger 12-inch G600 TXi flight display, TXi EIS, GTN™ 750Xi GPS/NAV/COMM and GFC™ 600 digital autopilot — is a cutting-edge solution for the CJ1 cockpit. The system offers situational aware
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom